Publications by authors named "Mihaela C Munteanu"
Lack of patient diversity in clinical trial enrollment remains an obstacle to achieving equitable healthcare outcomes. Under-representation has resulted in non-generalizable clinical knowledge, inequitable access to treatment, and health disparities among minority and disadvantaged groups. A multidisciplinary panel was convened to consider the challenges of diverse patient accrual and provide actionable solutions to improve representation in clinical trials.
View Article and Find Full Text PDFArticle Synopsis
- The trial assessed the effectiveness of adding epacadostat, an IDO1 inhibitor, to pembrolizumab and chemotherapy for treating advanced non-small cell lung cancer (NSCLC) without targetable mutations.
- Patients were divided into three treatment groups: one receiving the combination of epacadostat, pembrolizumab, and chemotherapy; another receiving epacadostat and pembrolizumab; and a placebo group also receiving pembrolizumab and chemotherapy.
- Results showed that the combination of epacadostat, pembrolizumab, and chemotherapy had a lower objective response rate (26.4%) compared to the placebo combination (44.8%), indicating that adding epacadostat might not improve treatment outcomes for patients.
Background CD37 is expressed on B-cell lymphoid malignancies, thus making it an attractive candidate for targeted therapy in non-Hodgkin lymphoma (NHL). IMGN529 is an antibody-drug conjugate comprising a CD37-binding antibody linked to the maytansinoid DM1, a potent anti-mitotic agent. Methods This first-in-human, phase 1 trial recruited adult patients with relapsed or refractory B-cell NHL.
View Article and Find Full Text PDFUnlabelled: In a single-arm, phase 2 clinical trial, bendamustine-rituximab (BR) demonstrated an overall response rate of 82% among 45 patients with relapsed or refractory mantle cell lymphoma (MCL), with manageable tolerability. A prespecified F-FDG PET analysis was conducted to assess the predictive value of the metabolic response to BR compared with the response by International Working Group (IWG) criteria.
Methods: Adult patients with relapsed or refractory MCL underwent F-FDG PET at screening and after 6 cycles of BR therapy.
Purpose: Bendamustine is used in chronic lymphocytic leukemia (first-line) and indolent B-cell non-Hodgkin lymphoma (NHL) that progressed during/within 6 months of treatment with rituximab or a rituximab-containing regimen. This study was a postapproval commitment to investigate bendamustine's effect on cardiac repolarization in treatment-naïve adults with advanced indolent NHL/mantle cell lymphoma (MCL).
Methods: In this multicenter, open-label, phase 3 study, patients received 6-8 28-day cycles of bendamustine (90 mg/m(2), days 1 and 2) and rituximab (375 mg/m(2), day 1).
Purpose: Bendamustine plus rituximab has been reported to be effective in treating lymphoid malignancies. This analysis investigated the potential for drug-drug interactions between the drugs in patients with indolent non-Hodgkin lymphoma or mantle cell lymphoma.
Methods: Data were derived from a bendamustine-rituximab combination therapy study, a bendamustine monotherapy study, and published literature on rituximab monotherapy and combination therapy.
Purpose: A fully human monoclonal antibody to anti-alpha(v) integrins (CNTO 95) has been shown to inhibit angiogenesis and tumor growth in preclinical studies. We assessed the safety and pharmacokinetics of CNTO 95 in patients with advanced refractory solid tumors.
Experimental Design: In this phase I trial, CNTO 95 (0.